IZOZF - Izotropic's Breast CT Radiation Imaging Subsystem Powered on and Takes Initial Images

(TheNewswire)

VANCOUVER, BC - TheNewswire - November 22,2021 - Izotropic Corporation (“ Izotropic ” or the “ Company ”) (C NSX: IZO. CN ) (OTC: IZOZF ) (FSE: 1R3 ), a Company commercializing a dedicatedbreast CT (computed tomography) imaging platform, IzoView, for themore accurate detection and diagnosis of breast cancers providesupdates on the following:

• - IzoView radiation imaging subsystem assembly,functionality, and installation features

  - Formal radiation safety certification

  - Initial phantom image acquisition and imagereconstruction software

Izotropic is pleased to announce that its engineeringteams have successfully built and assembled IzoView’s radiationimaging subsystem, and it has been formally certified as safe tooperate. This milestone enables the subsystem, which is now takingstatic images, to be characterized and optimized for 360-degree imageacquisition.

Radiation Imaging Subsystem: Safetyand minimized installation costs

IzoView’s radiation imaging subsystem has beenpowered on, tested, and emits less radiation into the surrounding areathan diagnostic mammography. A formal radiation safety certificationwas awarded upon completion of radiation safety testing that wasconducted by the governing health authority.

Radiation safety testing is completed by measuring theamount of radiation output into the surrounding area or imaging suiteduring a single scan. Radiation-based imaging devices typicallyrequire a radiation-safe leaded room or a leaded divider for thetechnician to stand behind during the scan. Certain levels ofradiation leakage that result from radiation-based imaging devicesinto the imaging suite are allowable under standard safetyrequirements, but measures must be taken to protect patients and staffwith increased installation and set up costs to the customer. IzoViewhas been designed with specific features to minimize customerinstallation and shielding costs while providing enhanced patient andtechnician safety.

IzoView’s Initial Images

The radiation imaging subsystem is now acquiring and producingpreliminary images.  Images have been taken using different types ofphantoms which are stand-in objects in place of human tissue. Phantomshave been used to calibrate the imaging system in relation to thedetector and the geometry of the imaging system for the 3Dreconstruction software.

With this milestone achieved, engineering teams can nowbegin optimizing and calibrating the imaging subsystem to acquireimages in 360 degrees- the key differentiator for IzoView’s true 3Dimages versus 2D mammography or tomosynthesis images.

The preliminary image data being produced will supportthe advancement of the new image reconstruction software that utilizesdeep machine learning algorithms currently in development inpartnership with Johns Hopkins University School ofMedicine.

Phantom image acquisition, which was initiallyprojected to begin in Q1 2022, has begun ahead of schedule.

Messages from CEO and EVP of ProductEngineering

“This next stage is really about fine-tuning keyvariables in our hardware and software upgrades as they work togetherto create the high-resolution 3D images our Breast CT systemoffers,” said Dr. Younes Achkire, Executive Vice President ofProduct Engineering. “We’re doing this so when we ramp up toproduction for our clinical study units, our images and deviceoperation will be 100% consistent.”

CEO, Dr. John McGraw, stated: “Even with ongoingglobal supply chain issues, we have our key components: generator,power unit, detector, and computer, and we can power it all on andproduce images. I’m very proud of what we’re continuing toaccomplish at Izotropic.”

ON BEHALF OF THE BOARD

For investor relations inquiries,contact:

James Berard
Email: jberard@izocorp.com
Cell: 778-228-2314
Toll Free: 1-833-IZOCORP ext.1

About Izotropic Corporation

Izotropic Corporation is the only publicly tradedcompany commercializing a dedicated breast CT imaging platform,IzoView, for the more accurate detection and diagnosis of breastcancers.  To expedite patient and provider access to IzoView,Izotropic’s initial clinical study intends to demonstrate superiorperformance of diagnostic breast CT imaging over diagnosticmammography procedures and will initiate in Q2 2022. In follow-onclinical studies, Izotropic intends to validate platform applicationsincluding breast screening in radiology, treatment planning andmonitoring in surgical oncology, and breast reconstruction and implantmonitoring in plastic and reconstructive surgery.

More information about Izotropic Corporation can befound on its website at izocorp.com and by reviewing itsprofile on SEDAR at sedar.com

Forward-Looking Statements

This document may contain statements that are“Forward-Looking Statements,” which are based upon the currentestimates, assumptions, projections and expectations of theCompany’s management, business, and its knowledge of the relevantmarket and economic environment in which it operates. The Company hastried, where possible, to identify such information and statements byusing words such as “anticipate,” “believe,” “envision,”“estimate,” “expect,” “intend,” “may,” “plan,”“predict,” “project,” “target,” “potential,”“will,” “would,” “could,” “should,” “continue,”“contemplate” and other similar expressions and derivationsthereof in connection with any discussion of future events, trends orprospects or future operating or financial performance, although notall forward-looking statements contain these identifying words. Thesestatements are not guarantees of performance and involve risks anduncertainties that are difficult to control or predict, and as such,they may cause future results of the Company’s activity to differsignificantly from the content and implications of such statements.Forward-Looking Statements are pertinent only as of the date on whichthey are made, and the Company undertakes no obligation to update orrevise any Forward-Looking Statements to reflect new information orthe occurrence of future events or circumstances unless otherwiserequired to do so by law. Neither the Companynor its shareholders, officers, and consultants, shall be liable forany action and the results of any action taken by any person based onthe information contained herein, including without limitation thepurchase or sale of Company securities. Nothing in this documentshould be deemed to be medical or other advice of any kind.

Copyright (c) 2021 TheNewswire - All rights reserved.